Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients.

[1]  M. Verbeek,et al.  Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid β42 and Tau Proteins , 2007 .

[2]  Z. Stelmasiak,et al.  The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis , 2006, Journal of Neural Transmission.

[3]  K. Blennow,et al.  Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease , 2006, Neurobiology of Aging.

[4]  K. Rostásy,et al.  Tau, Phospho-Tau, and S-100B in the Cerebrospinal Fluid of Children With Multiple Sclerosis , 2005, Journal of child neurology.

[5]  J. Kassubek,et al.  Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis , 2005, Multiple sclerosis.

[6]  J. Wiltfang,et al.  Follow-Up Investigations of Tau Protein and S-100B Levels in Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease , 2005, Dementia and Geriatric Cognitive Disorders.

[7]  Anders Wallin,et al.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.

[8]  A. Hołownia,et al.  Cerebrospinal Fluid Excitatory Amino Acids and Tau Protein in Children with Acute Lymphoblastic Leukemia Treated according to the BFM Protocol , 2004, Acta Haematologica.

[9]  M. R. Bigio,et al.  Cellular Damage and Prevention in Childhood Hydrocephalus , 2004 .

[10]  H. Hampel,et al.  Total and Phosphorylated Tau Proteins: Evaluation as Core Biomarker Candidates in Frontotemporal Dementia , 2004, Dementia and Geriatric Cognitive Disorders.

[11]  K. Yasuda,et al.  Tau protein in the cerebrospinal fluid is a marker of brain injury after aortic surgery. , 2004, The Annals of thoracic surgery.

[12]  J. Archelos,et al.  Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG , 2004, Journal of Neurology.

[13]  H. Vanderstichele,et al.  Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. , 2004, Neurotoxicology.

[14]  C. Bouras,et al.  Cerebrospinal fluid tau and Aβ42 concentrations in healthy subjects: delineation of reference intervals and their limitations , 2004, Clinical chemistry and laboratory medicine.

[15]  M. Tullberg,et al.  Differences in cerebrospinal fluid dynamics do not affect the levels of biochemical markers in ventricular CSF from patients with aqueductal stenosis and idiopathic normal pressure hydrocephalus , 2004, European journal of neurology.

[16]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[17]  K. Blennow,et al.  CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry , 2003, Brain Research Bulletin.

[18]  H. Vanderstichele,et al.  Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias , 2003, Molecular Psychiatry.

[19]  A Drzezga,et al.  Tau and A&bgr;42 protein in CSF of patients with frontotemporal degeneration , 2002, Neurology.

[20]  K. Blennow,et al.  Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms , 2002, Dementia and Geriatric Cognitive Disorders.

[21]  K. Blennow,et al.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.

[22]  A I Canady,et al.  Axonal damage associated with enlargement of ventricles during hydrocephalus: A silver impregnation study , 2001, Neurological research.

[23]  H. Reiber,et al.  Dynamics of brain-derived proteins in cerebrospinal fluid. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[24]  Harald Hampel,et al.  CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease , 2001, Molecular Neurobiology.

[25]  K. Blennow,et al.  Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E ε4 Frequency, but No Tau Gene Mutations , 2001, Experimental Neurology.

[26]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[27]  L. Parnetti,et al.  CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies , 2001, Neurological Sciences.

[28]  K. Blennow,et al.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke , 2001, Neuroscience Letters.

[29]  H. Vanderstichele,et al.  Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies , 2000, Leukemia.

[30]  H. Hampel,et al.  Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients , 2000, Neuroscience Letters.

[31]  T. Kudo,et al.  Tau protein is a potential biological marker for normal pressure hydrocephalus , 2000, Psychiatry and clinical neurosciences.

[32]  J. Kornhuber,et al.  Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease , 2000, Neurology.

[33]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease , 2000, Neuroscience Letters.

[34]  K. Blennow,et al.  Increased cerebrospinal fluid protein tau concentration in neuro-AIDS , 1999, Journal of the Neurological Sciences.

[35]  K. Blennow,et al.  Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. , 1999, Neurology.

[36]  Hiroyuki Arai,et al.  Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease , 1999, Neuroscience Letters.

[37]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[38]  M. Rossor,et al.  Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease , 1999, Neuroscience Letters.

[39]  M. Goedert,et al.  Tau protein pathology in neurodegenerative diseases , 1998, Trends in Neurosciences.

[40]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[41]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[42]  S. Hirai,et al.  Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease , 1998, Journal of the Neurological Sciences.

[43]  K. Blennow,et al.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[44]  J. Trojanowski,et al.  Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. , 1997, Biochemical and biophysical research communications.

[45]  J. Kornhuber,et al.  Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease , 1997, Neuroscience Letters.

[46]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[47]  M. Goedert.  Tau protein and the neurofibrillary pathology of Alzheimer's disease , 1993, Trends in Neurosciences.

[48]  A. Frankfurter,et al.  The distribution of tau in the mammalian central nervous system , 1985, The Journal of cell biology.

[49]  R. Weller,et al.  Cerebral biopsy and assessment of brain damage in hydrocephalus. , 1975, Archives of disease in childhood.

[50]  P. Scheltens,et al.  Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. , 2005, Clinical chemistry.

[51]  M. D. Bigio,et al.  Neuropathological changes caused by hydrocephalus , 2004, Acta Neuropathologica.

[52]  A. Grubb,et al.  The cerebrospinal fluid and plasma concentrations of γ-trace and β2-microglobulin at various ages and in neurological disorders , 2004, Journal of Neurology.

[53]  D. Galasko.  Cerebrospinal fluid levels of Aβ42 and tau: potential markers of Alzheimer’s disease , 1998 .

[54]  J. McAllister,et al.  Neonatal hydrocephalus: Mechanisms and consequences , 1998 .